Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

89 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
[Genetic predisposition and ovarian cancer].
Coupier I, Gauthier-Villars M, This P, Stoppa-Lyonnet D. Coupier I, et al. Rev Prat. 2004 Oct 31;54(16):1757-62. Rev Prat. 2004. PMID: 15630879 Review. French.
[Explosive growth of uterine leiomyomas and carcinologic ovarian risk in a non-menopausal patient with BRCA1-BRCA2 mutation treated by tamoxifen].
Doridot V, This P, Clough KB. Doridot V, et al. J Gynecol Obstet Biol Reprod (Paris). 2002 Nov;31(7):677-80. J Gynecol Obstet Biol Reprod (Paris). 2002. PMID: 12457141 French.
OBJECTIVE: To report the case of significant growth of a myoma in a premenopausal woman with a suspicion of BRCA1 and BRCA2 mutation, treated by tamoxifen for a hormonodependent breast cancer and to point out the carcinologic ovarian risks with a mutation BRCA1-BRCA2 in this
OBJECTIVE: To report the case of significant growth of a myoma in a premenopausal woman with a suspicion of BRCA1 and BRCA2 mutation, treate …
[Approach of menopause in women at risk for breast cancer].
This P, Cormier C. This P, et al. Gynecol Obstet Fertil. 2002 Feb;30(2):101-13. doi: 10.1016/s1297-9589(01)00276-4. Gynecol Obstet Fertil. 2002. PMID: 11910878 Review. French.
The small but significant increase in risk of discovering breast cancer in women with hormone replacement therapy and the recent discussion of coronary benefit of this treatment have led many authors to insist on the necessity to evaluate the benefit/risks ratio before adm …
The small but significant increase in risk of discovering breast cancer in women with hormone replacement therapy and the recent discussion …
[HRT in post menopausal women and breast cancer at the Institut Curie].
Czernichow C, This P, Asselain B, Falcou MC, Savignoni A, Salmon RJ; Groupe sein de l'Institut Curie, Sigal-Zafrani B. Czernichow C, et al. Bull Cancer. 2007 May;94(5):469-75. Bull Cancer. 2007. PMID: 17535785 French.
Surgical procedure, locoregional recurrence, metastasis, disease free and global survival were compared bet the patient who received an HRT versus the patients who didn't receive this treatment Mammographic diagnosis was more frequent in the HRT group and the age at diagno …
Surgical procedure, locoregional recurrence, metastasis, disease free and global survival were compared bet the patient who received an HRT …
A critical view of the effects of phytoestrogens on hot flashes and breast cancer risk.
This P, de Cremoux P, Leclercq G, Jacquot Y. This P, et al. Maturitas. 2011 Nov;70(3):222-6. doi: 10.1016/j.maturitas.2011.07.001. Epub 2011 Aug 2. Maturitas. 2011. PMID: 21813250 Review.
In this review, we will address the effects of PE on hot flashes and breast cancer risk as well as the questions raised on a chemical point of view. ...
In this review, we will address the effects of PE on hot flashes and breast cancer risk as well as the questions raised on a chemical …
[Implications of genetic risk factors in breast cancer: culprit genes and associated malignancies].
Stoppa-Lyonnet D, Buecher B, Houdayer C, de Pauw A, Gauthier-Villars M, de la Rochefordière A, This P, Asselain B, Andrieu N. Stoppa-Lyonnet D, et al. Bull Acad Natl Med. 2009 Dec;193(9):2063-83; discussion 2084-5. Bull Acad Natl Med. 2009. PMID: 20690207 French.
Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.
Kirova YM, Savignoni A, Sigal-Zafrani B, de La Rochefordiere A, Salmon RJ, This P, Asselain B, Stoppa-Lyonnet D, Fourquet A. Kirova YM, et al. Breast Cancer Res Treat. 2010 Feb;120(1):119-26. doi: 10.1007/s10549-009-0685-6. Epub 2009 Dec 24. Breast Cancer Res Treat. 2010. PMID: 20033769 Review.

Tumours in mutation carriers were more likely to be grade III (P < 10(-4)) and oestrogen receptor negative (P = 0.005) than in non-carriers and controls. ...There was no significant difference in ipsilateral tumours between mutation carriers, non-carriers and con

Tumours in mutation carriers were more likely to be grade III (P < 10(-4)) and oestrogen receptor negative (P = 0.005) than

Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.
Laki F, Kirova YM, This P, Plancher C, Asselain B, Sastre X, Stoppa-Lyonnet D, Salmon R; IC-BOCRSG IC-BOCRSG: Institut Curie - Breast Ovary Cancer Risk Study Group. Laki F, et al. Cancer. 2007 May 1;109(9):1784-90. doi: 10.1002/cncr.22603. Cancer. 2007. PMID: 17351952
The median age at SO was 44 (BRCA1) and 49.5 (BRCA2) years for women without previous BC (not significant) and 48 (BRCA1) and 53 BRCA2) years (P=.03) for women with previous BC. ...However, a longer follow-up and larger series are required to more precisely evaluate the be …
The median age at SO was 44 (BRCA1) and 49.5 (BRCA2) years for women without previous BC (not significant) and 48 (BRCA1) and 53 BRCA2) year …
89 results
Jump to page
Feedback